Rheumatoid arthritis: Regulation of synovial inflammation

International Journal of Biochemistry and Cell Biology

Volumn 36, Issue 3, 2004, Pages 372-378

  Sweeney, Susan E ^a   Firestein, Gary S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytokines; Inflammation; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CIPEMASTAT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYTOKINE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; INTERLEUKIN 4; METALLOPROTEINASE INHIBITOR; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

APOPTOSIS; B LYMPHOCYTE ACTIVATION; BONE DESTRUCTION; CARTILAGE; CELL INFILTRATION; CLINICAL TRIAL; DRUG EFFICACY; FIBROSIS; HUMAN; INFLAMMATORY CELL; NONHUMAN; OSTEOCLAST; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SYMPTOMATOLOGY; SYNOVIOCYTE; SYNOVITIS; SYNOVIUM; TREATMENT OUTCOME;

EID: 0347480219     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(03)00259-0     Document Type: Short Survey

References (17)

1. Chabaud M., Durand J.M., Buchs N.et al. Human interleukin-17: A T cell derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis and Rheumatism. 42:1999;963-970.
2. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature. 423:2003;356-361.
3. Firestein G.S., Zvaifler N.J. How important are T cells in chronic rheumatoid synovitis? Arthritis and Rheumatism. 33:1990;768-773.
4. Gabay C., Arend W.P. Treatment of rheumatoid arthritis with IL-1 inhibitors. Springer Seminars in Immunopathology. 20:1998;229-246.
5. Gracie J.A., Forsey R.J., Chan W.L., Gilmour A., Leung B.P., Greer M.R., Kennedy K., Carter R., Wei X.Q., Xu D., Field M., Foulis A., Liew F.Y., McInnes I.B. A proinflammatory role for IL-18 in rheumatoid arthritis. Journal of Clinical Investigation. 104:1999;1393-1401.
6. Han Z., Boyle D.L., Manning A.M., Firestein G.S. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity. 28:1998;197-208.
7. Kong Y.Y., Feige U., Sarosi I., Balon B., Tafuri A., Morony S., Capparelli C., Li J., Elliott R., McCabe S., Wong T., Campagnuolo G., Moran E., Bogoch E.R., Van G., Nguyen L.T., Ohashi P.S., Lacey D.L., Fish E., Boyle W.J., Penninger J.M. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 402:1999;304-309.
8. Loetscher P., Uguccioni M., Bordoli L., Baggiolini M., Moser B., Chizzolini C., Dayer J.M. CCR5 is characteristic of Th1 lymphocytes. Nature. 391:1998;344-345.
9. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., Ettlinger R.E., Cohen S., Koopman W.J., Mohler K., Widmer M.B., Blosch C.M. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. The New England Journal of Medicine. 337:1997;141-147.
10. Moreland L.W. Potential biologic agents for treating rheumatoid arthritis. Rheumatic Diseases Clinics of North America. 27:2001;445-491.
11. Schett G., Tohidast-Akrad M., Smolen J.S., Schmid B.J., Steiner C.W., Bitzan P., Zenz P., Redlich K., Xu Q., Steiner G. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis and Rheumatism. 43:2000;2501-2512.
12. Szekanecz Z., Koch A.E. Update on Synovitis. Current Rheumatology Reports. 3:2001;53-63.
13. Szekanecz Z., Kunkel S.L., Strieter R.M., Koch A.E. Chemokines in rheumatoid arthritis. Springer Seminars in Immunopathology. 20:1998;115-132.
14. Tak P.P., Zvaifler N.J., Green D.R., Firestein G.S. Rheumatoid arthritis and p53: How oxidative stress might alter the course of inflammatory diseases. Immunology Today. 21:2000;78-82.
15. Vita S.D.et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells. Arthritis and Rheumatism. 46:2002;2029-2033.
16. Wendling J.M., Racadot E., Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. Journal of Rheumatology. 20:1993;259-262.
17. Ziolkowska M., Koc A., Luszczykiewicz G., Ksiezopolska-Pietrzak K., Klimczak E., Chwalinska-Sadowska H., Maslinski W. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. Journal of Immunology. 164:2000;2832-2838.